Growth of orphan drug market puts the World Orphan Drug Congress USA in the spotlight

Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development. In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to …

Orphan drugs, no longer orphan?

Have orphan drugs found a home? It seems that this is the case for a lot of rare disease therapies being developed, as pharma and biotechs, along with investors, have understood that producing orphan drugs can be a potent money maker. It all started with the first orphan drug approved by the FDA from Genzyme to treat Gaucher's Disease and …

Is China prepared for orphan drug development and access?

As the orphan drug market grows exponentially, everyone is looking into China and whether the country is prepared to provide access for therapies to rare disease patients. Pharma companies like Genzyme have made strong efforts to introduce one of its orphan drugs in China and into the healthcare system in force. China has reached a remarkable achievement in the past …